OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. OCREVUS (ocrelizumab) injection can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.
Therapeutic indications and Usage
OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. Active ingredient: ocrelizumab Inactive ingredients: glacial acetic acid, polysorbate 20, sodium acetate trihydrate, trehalose dihydrate.
DISEASE INDICATIONS: Multiple Sclerosis
MANUFACTURER: Roche Registration Limited
DOSAGE FORMS AND STRENGTHS: Injection: 300 mg/10 mL (30 mg/mL) clear or slightly opalescent, and colorless to pale brown solution in a single-dose vial.
MEDICINE APPROVED BY: European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Source Details: Patient Information
Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "OCREVUS (ocrelizumab) injection" in quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Health Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for OCREVUS (ocrelizumab) injection price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
Ocrelizumab, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. It was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed by Hoffmann–La Roche's subsidiary Genentech under the trade name Ocrevus. With the approval, the FDA also required the company to conduct several Phase IV clinical trials to better understand whether the drug is safe and effective in young people, cancer risks, and effects on pregnant women and children they might bear. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "OCREVUS (ocrelizumab) injection" in quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Visakhapatnam, Surat, Jaipur, Coimbatore, Kanpur, Nagpur, Raipur, Kochi, Kozhikode, Nashik, Salem, Thiruvananthapuram, Madurai, Jodhpur, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. with over 20 years of domain experience.
For procurement cost of OCREVUS (ocrelizumab) injection in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the OCREVUS (ocrelizumab) injection medicine cost price in India.
The order for OCREVUS (ocrelizumab) injection will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of OCREVUS (ocrelizumab) injection from authorised distributor.
Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells. Ocrelizumab is a glycosylated immunoglobulin G1 (IgG1) with a molecular mass of approximately 145 kDa. OCREVUS (ocrelizumab) Injection for intravenous infusion is a preservative-free, sterile, clear or slightly opalescent, and colorless to pale brown solution supplied in single-dose vials. Each mL of solution contains 30 mg ocrelizumab, glacial acetic acid (0.25 mg), polysorbate 20 (0.2 mg), sodium acetate trihydrate (2.14 mg), and trehalose dihydrate (40 mg) at pH 5.3. In the US, ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults or for the treatment of primary progressive MS, in adults. It is administered by intravenous infusion. In the EU, ocrelizumab is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features and for the treatment of adults with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
OCREVUS (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017.
DOSAGE FORMS AND STRENGTHS: Injection: 300 mg/10 mL (30 mg/mL) clear or slightly opalescent, and colorless to pale brown solution in a single-dose vial. Ocrevus isn't a type of chemotherapy, but it is an immunosuppressant drug. Chemotherapy works by destroying cells that grow more rapidly than healthy cells, such as cancer cells. Immunosuppressant drugs work by lessening the activity of your immune system.
For OCREVUS (ocrelizumab) injectionIndications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Summary of Product Characteristics [FDA]: Ocrevus (ocrelizumab) [PDF] Genentech, March 2017
FDA News Release: FDA approves new drug to treat multiple sclerosis September 2017
Wikipedia. Multiple sclerosis cited on 19/05/21017
Summary of Product Characteristics [TGA]: Ocrevus (ocrelizumab) [PDF] Roche, July 2017
Summary of Product Characteristics [EMA]: Ocrevus (ocrelizumab) [PDF] Roche, January 2018
6. Summary of Product Characteristics [Health Canada]: Ocrevus (ocrelizumab) [PDF] Roche, April 2018
Step 1. Send a request for your medicine online:-Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Step 2. Verification of documents:-We verify your a prescription and necessary documents to import drugs in quantities for personal use.
Step 3. Permission to Import:-After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.
Step 4. We source your medicine:-Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
Step 5. Delivery of medicine:-After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.
Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
OCREVUS (ocrelizumab) injection price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
OCREVUS (ocrelizumab) injection price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
OCREVUS (ocrelizumab) injection price in North America – Mexico.
OCREVUS (ocrelizumab) injection price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
OCREVUS (ocrelizumab) injection price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
OCREVUS (ocrelizumab) injection price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
OCREVUS (ocrelizumab) injection price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
OCREVUS (ocrelizumab) injection price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.